TITLE

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I

AUTHOR(S)
Shah, P L; Scott, S F; Fuchs, H J; Geddes, D M; Hodson, M E
PUB. DATE
April 1995
SOURCE
Thorax;Apr1995, Vol. 50 Issue 4, p333
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66066471

 

Related Articles

  • Endotracheal DNase for atelectasis in ventilated neonates. MacKinnon, R; Wheeler, K I; Sokol, J // Journal of Perinatology;Dec2011, Vol. 31 Issue 12, p799 

    Management of atelectasis and lung collapse in ventilated neonates remains a common challenge in the neonatal intensive care unit. Recombinant human DNase (rhDNase) is an established treatment of atelectasis in cystic fibrosis and its use is also reported in the management of asthma, respiratory...

  • Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Suri, R.; Grieve, R.; Normond, C.; Metcalfe, C.; Thompson, S.; Wallis, C.; Bush, A. // Thorax;Oct2002, Vol. 57 Issue 10, p841 

    Background: Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cystic fibrosis (CF). An alternative lower cost therapy is hypertonic saline (HS), which has been shown to improve lung function in short term studies. This study compares the costs and...

  • DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. Cobos, N.; Danés, I.; Gartner, S.; González, M.; Liñán, S.; Arnau, J. M. // European Journal of Pediatrics;2000, Vol. 159 Issue 3, p176 

    Abstract Short-term clinical trials with DNase have shown minor to moderate benefits in cystic fibrosis patients. This study was performed to analyse the effectiveness of DNase use in daily practice and to obtain information on its effects in the long term and at different disease stages....

  • Vehicles for gene therapy. Wilson, James M. // Nature;10/21/1993, Vol. 365 Issue 6448, p691 

    Discusses a report on a trial of cystic fibrosis gene therapy in humans. Use of recombinant adenovirus; Identification of the gene responsible for cystic fibrosis.

  • Novel agents in cystic fibrosis. Storey, Shane; Wald, Graeme // Nature Reviews Drug Discovery;Jul2008, Vol. 7 Issue 7, p555 

    The article provides information on several therapeutic agents that improve the treatment of cystic fibrosis. It states that Pulmozyme drug from Genentech Inc. is a recombinant human DNase, which reduces mucus viscosity in the lungs. Moreover, it notes that the hyperosmolar agent Bronchitol is...

  • Pulmonary.  // Africa Health;Jul2011, Vol. 33 Issue 5, p59 

    The article reports on a 5-year follow-up for acute respiratory distress syndrome (ARDS), the large part played by nebulised recombinant human DNase in adults with cystic fibrosis, and the use of inhaled long-acting bronchodilators for patients with severe chronic obstructive pulmonary disease.

  • Thumbs up for DNase.  // Drug Topics;9/6/93, Vol. 137 Issue 17, p64 

    Reports on a Food and Drug Administration advisory panel's recommendation for approval of DNase, Genentech Inc.'s investigational treatment for cystic fibrosis. Pulmozyme as brandname.

  • Cystic fibrosis and survival in patients with advanced lung disease. Dasenbrook, Elliott C. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/12/2011, Vol. 342 Issue 7797, p558 

    The author reflects on a study on adult patients with cystic fibrosis and advanced lung disease, by George and colleagues, published within the issue. The study found that mortality among patients with cystic fibrosis and advanced lung disease who were treated at the Royal Brompton Hospital in...

  • Mucolytic therapy in cystic fibrosis. Wallis, Colin // Journal of the Royal Society of Medicine (Supplement);Jul2001, Vol. 94 Issue 40, p17 

    The article discusses the role of mucolytics in cystic fibrosis (CF). It presents terminologies and investigative techniques used in the study of sputum rheology when assessing the results of trials on mucolytic agent. It offers information on several products available that can assist in the...

  • Single-step Purification by Lectin Affinity and Deglycosylation Analysis of Recombinant Human and Porcine Deoxyribonucleases I Expressed in COS-7 Cells. Fujihara, Junko; Hieda, Yoko; Xue, Yuying; Okui, Izumi; Kataoka, Kaori; Takeshita, Haruo // Biotechnology Letters;Feb2006, Vol. 28 Issue 4, p215 

    Human and porcine recombinant deoxyribonucleases I (DNases I) were expressed in COS-7 cells, and purified by a single-step procedure. Since affinities for concanavalin A (Con A) and wheatgerm agglutinin (WGA) were strong in these recombinant DNases I, purification using Con A–WGA...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics